Jiancheng Hu is a Principal Investigator in the Division of Cellular and Molecular Research, National Cancer Centre Singapore, and an Asistant Professor in the Cancer and Stem Cell Program, Duke-NUS Medical School, Singapore. He received his B.S. in 1996 from the East China University of Science and Technology, M.S. in 2001 from Peking University, China , and Ph.D. in 2007 from University of Colorado, USA.
During Dr Hu’s training, he developed a keen interest on cell signaling. As a postdoctoral fellow in Andrey Shaw’s lab at Washington University in Saint Louis and Howard Hughes Medical Institute (2008~2014), USA, he studied the molecular mechanism(s) that regulates the Ras/RAF/MEK/ERK signaling and how this signaling pathway was aberrantly activated in cancer and developmental diseases. In 2014, He was recruited to National Cancer Centre Singapore as a Pricinpal Investigator and Duke-NUS Medical School as an assistant professor.
Dr Hu’s research focuses on: (1) the regulatory mechanism of RAF/MEK/ERK kinase cascade and other oncogenic protein kinases; (2) the molecular basis that underlie Intrinsic and acquired resistance of kinase inhibitors in cancer therapy; (3) the development of novel protein kinase inhibitors for cancer treatment.
